Science Corp. raises $230M as it races to bring its brain implant to market

Brain-Computer Interface Startup Science Corp. Raises $230M, Poised to Launch First Market-Ready Vision Restoration Device

In a landmark moment for neurotechnology, Science Corporation—the ambitious brain-computer interface (BCI) startup founded by Neuralink co-founder Max Hodak—has announced a $230 million Series C funding round, propelling its valuation to an impressive $1.5 billion. This latest infusion of capital brings the company’s total funding to $490 million and underscores the growing confidence in Science Corp.’s vision to bring life-changing neurotechnology to market.

While much of the venture capital world has been captivated by the rapid rise of artificial intelligence, Hodak has been quietly steering Science Corp. toward a different frontier: the seamless integration of human biology and advanced computing. The company’s flagship project, PRIMA, is a revolutionary brain-computer interface designed to restore functional vision to individuals suffering from advanced macular degeneration—a condition that affects millions worldwide and often leads to irreversible blindness.

PRIMA: A Grain-of-Rice-Sized Revolution in Vision Restoration

At the heart of Science Corp.’s breakthrough is PRIMA, a chip smaller than a grain of rice that, when implanted in the eye, works in concert with camera-equipped glasses to bypass damaged retinal cells and directly stimulate the visual cortex. This cutting-edge approach has the potential to restore the ability to read, recognize faces, and navigate the world for those who have lost their sight due to macular degeneration.

The technology’s journey to this point is as remarkable as its promise. In 2024, Science Corp. acquired the assets of Pixium Vision, a French company that had been developing similar retinal implants but had not yet achieved commercial success. Science Corp. took the baton, refining the technology, completing ongoing clinical trials, and generating its own compelling data.

Clinical Triumphs and the Dawn of a New Era in Medicine

The results from Science Corp.’s trials are nothing short of extraordinary. Across 47 patients in Europe and the United States, an astounding 80% demonstrated meaningful improvement in visual acuity, with many able to read letters, numbers, and words for the first time in years. As Hodak himself noted in a December interview with TechCrunch, “To my knowledge, this is the first time that restoration of the ability to fluently read has ever been definitively shown in blind patients.” The significance of this achievement cannot be overstated—it represents a tangible, life-altering breakthrough for individuals who have long been told that their vision loss is irreversible.

The company’s pioneering work has not gone unnoticed. PRIMA’s potential has earned it a coveted spot on the cover of Time magazine, signaling both the scientific and cultural impact of Science Corp.’s efforts.

Navigating the Regulatory Landscape: Europe First, U.S. Next

While the technology is ready, the path to market is governed by rigorous regulatory oversight. Science Corp. has submitted a CE mark application to the European Union, with approval expected in mid-2026. This would make PRIMA the first brain-computer interface product to reach the market—a milestone that could redefine the boundaries of medical technology.

Germany is poised to be the first country to offer PRIMA to patients, thanks to its established pathways for early access to innovative medical technologies. In the United States, discussions with the FDA are ongoing, and the company is optimistic about bringing its life-changing device to American patients in the near future.

Beyond Vision: A Broad Portfolio of Neurotechnological Innovation

Science Corp. is not resting on its laurels. The company is actively expanding its PRIMA trial program to include patients with Stargardt disease and retinitis pigmentosa—two inherited retinal conditions that are leading causes of vision loss in young adults. This expansion reflects Science Corp.’s commitment to addressing a broad spectrum of visual impairments.

But the company’s ambitions extend far beyond vision restoration. Science Corp. is also developing a biohybrid neural interface, an innovative program that involves growing engineered neurons from stem cells onto a waffle-like device that sits on the brain’s surface. This device forms biological connections with existing neural circuits, opening the door to a new era of brain-computer integration.

Vessel: Revolutionizing Organ Preservation and Transport

In a surprising but strategic move, Science Corp. has launched a new business line called Vessel, focused on organ preservation and transport. Vessel aims to develop miniaturized perfusion technology—a method of keeping organs alive and healthy outside the body by continuously supplying them with oxygenated blood. This technology could allow organs to be transported on commercial flights or even maintained by patients at home, rather than requiring costly and logistically complex ICU suites.

The potential impact of Vessel is immense: faster organ transport could mean more lives saved, and the ability to maintain organs outside of traditional hospital settings could democratize access to life-saving transplants.

A Star-Studded Investor Lineup and a Growing Team

The Series C funding round attracted a mix of new and returning investors, including Lightspeed Venture Partners, Khosla Ventures, Y Combinator, and Quiet Capital. Notably, IQT—a nonprofit investment firm that focuses on solutions for government organizations like the FBI and CIA—also participated, underscoring the broad appeal and potential applications of Science Corp.’s technology.

With 150 employees and a war chest of $490 million, Science Corp. is well-positioned to scale its operations, accelerate its research, and bring its groundbreaking technologies to the people who need them most.

The Road Ahead: A New Chapter in Human-Machine Symbiosis

As Science Corp. prepares to launch PRIMA and expand its portfolio of neurotechnological innovations, the company stands at the forefront of a new chapter in human-machine symbiosis. The implications are profound: restoring sight to the blind, enabling new forms of communication between the brain and computers, and even reimagining how we preserve and transport life-saving organs.

Max Hodak’s journey from Neuralink to Science Corp. reflects a broader trend in technology: the pursuit of transformative, human-centered innovation. As Science Corp. moves closer to its goal of bringing the first market-ready BCI to patients, the world watches with anticipation. The age of brain-computer interfaces is no longer a distant dream—it is rapidly becoming a reality, and Science Corp. is leading the charge.

Tags:
brain-computer interface, BCI, vision restoration, macular degeneration, PRIMA, Neuralink, Max Hodak, Science Corporation, neurotechnology, retinal implant, biohybrid neural interface, organ preservation, Vessel, perfusion technology, medical innovation, Time magazine, Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, FDA, CE mark, Stargardt disease, retinitis pigmentosa

Viral Sentences:

• “The first brain-computer interface company to get a product to market.”
• “A chip smaller than a grain of rice that restores sight.”
• “80% of blind patients regained the ability to read.”
• “The dawn of a new era in medicine.”
• “Restoring vision, redefining humanity.”
• “From Neuralink to Science Corp.: Max Hodak’s next big bet.”
• “The future of vision is here—and it’s smaller than a grain of rice.”
• “Revolutionizing organ transport: One flight away from saving a life.”
• “Brain-computer interfaces are no longer science fiction.”
• “The $1.5 billion bet on restoring sight to the blind.”

,